Cited by 901Cardiac Ischemia and ReperfusionDiabetes Treatment and ManagementAcute Myocardial Infarction Research

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion

Nikolaidis, Lazaros A., Mankad, Sunil, Sokos, George G., Miske, Glen, Shah, Ankur, Elahi, Dariush, Shannon, Richard P.·2004·Circulation

DOI 10.1161/01.cir.0000120505.91348.58

Open this paper in CoChat — free account

Abstract

Background— Glucose-insulin-potassium infusions are beneficial in uncomplicated patients with acute myocardial infarction (AMI) but are of unproven efficacy in AMI with left ventricular (LV) dysfunction because of volume requirements associated with glucose infusion. Glucagon-like peptide-1 (GLP-1) is a naturally occurring incretin with both insulinotropic and insulinomimetic properties that stimulate glucose uptake without the requirements for concomitant glucose infusion. Methods and Results— We investigated the safety and efficacy of a 72-hour infusion of GLP-1 (1.5 pmol/kg per minute) added to background therapy in 10 patients with AMI and LV ejection fraction (EF) <40% after successful primary angioplasty compared with 11 control patients. Echocardiograms were obtained after reperfusion and after the completion of the GLP-1 infusion. Baseline demographics and background therapy were similar, and both groups had severe LV dysfunction at baseline (LVEF=29±2%). GLP-1 significantly improved LVEF (from 29±2% to 39±2%, P <0.01), global wall motion score indexes (1.94±0.11→1.63±0.09, P <0.01), and regional wall motion score indexes (2.53±0.08→2.02±0.11, P <0.01) compared with control subjects. The benefits of GLP-1 were independent of AMI location or history of diabetes. GLP-1 was well tolerated, with only transient gastrointestinal effects. Conclusions— When added to standard therapy, GLP-1 infusion improved regional and global LV function in patients with AMI and severe systolic dysfunction after successful primary angioplasty.

Integrity signals

Registry

Crossref · 10.1161/01.cir.0000120505.91348.58

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Recommendations for Quantitation of the Left Ventricle by Two-Dimensional Echocardiography
Schiller, N. B., Shah, P. M., Crawford, M., DeMaria, A. N., Devereux, R. B., Feigenbaum, H., Gutgesell, H. P., Reichek, N., Sahn, D. J., Schnittger, I., et al. (1989) · Journal of the American Society of Echocardiography · doi:10.1016/s0894-7317(89)80014-8 · Cited by 8,110
Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year
Malmberg, K., Rydén, L., Efendic, S., Herlitz, J., Nicol, P., Waldenstrom, A., Wedel, H., & Welin, L. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)00126-k · Cited by 1,560
Clinical Prevention of Sudden Cardiac Death by n-3 Polyunsaturated Fatty Acids and Mechanism of Prevention of Arrhythmias by n-3 Fish Oils
Leaf, A., Kang, J. X., Xiao, Y.-F., & Billman, G. E. (2003) · Circulation · doi:10.1161/01.cir.0000069566.78305.33 · Cited by 605
Glucagon-Like Peptides
Drucker, D. J. (1998) · Diabetes · doi:10.2337/diab.47.2.159 · Cited by 598
Metabolic Modulation of Acute Myocardial Infarction
Díaz, R., Paolasso, E., Piegas, L. S., Tajer, C. D., Moreno, M. G., Corvalán, R., Isea, J., Romero, G., & Collaborative Group (1998) · Circulation · doi:10.1161/01.cir.98.21.2227 · Cited by 517
Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal.
D'Alessio, D., Kahn, S., Leusner, C. R., & Ensinck, J. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117225 · Cited by 309
Glucose-insulin-potassium infusion inpatients treated with primary angioplasty for acute myocardial infarction
van der Horst, I. C. C., Zijlstra, F., Hof, A. W. J. V. ’., Doggen, C. J. M., de Boer, M., Suryapranata, H., Hoorntje, J. C. A., Dambrink, J. E., Gans, R. O. B., & Bilo, H. J. G. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00830-1 · Cited by 259
Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7?36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships
Ritzel, R. A., �rskov, C., Holst, J. J., & Nauck, M. A. (1995) · Diabetologia · doi:10.1007/bf00401846 · Cited by 207
Insulin therapy as an adjunct toreperfusion after acute coronary ischemia
Sack, M. N., & Yellon, D. M. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00164-5 · Cited by 105
Glucose-Insulin-Potassium for Acute Myocardial Infarction
Apstein, C. S. (1998) · Circulation · doi:10.1161/01.cir.98.21.2223 · Cited by 95

Show all 15 references

Research works printed but not linked: 4

10.1161/circ.96.4.1074 · DOI
10.1161/circ.98.21.2227 · DOI
10.1161/circ.98.21.2223 · DOI
1987, Am Heart J, 102, 1038

Sorted by citations

Items 101–200 of 899

Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states
Nuche‐Berenguer, B., Moreno, P., Portal‐Núñez, S., Dapía, S., Esbrit, P., & Villanueva‐Peñacarrillo, M. L. (2009) · Regulatory Peptides · doi:10.1016/j.regpep.2009.06.010 · Cited by 144
Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?
Abdul-Ghani, M. A., DeFronzo, R. A., Prato, S. D., CHILTON, R. J., Singh, R., & Ryder, R. E. J. (2017) · Diabetes Care · doi:10.2337/dc16-2736 · Cited by 146
Cardiovascular effects of Glucagon-like peptide 1 (GLP-1) receptor agonists
Saraiva, F. K., & Sposito, A. C. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0142-7 · Cited by 143
Renal and Cardiac Effects of DPP-4 Inhibitors – from Preclinical Development to Clinical Research
Hocher, B., Reichetzeder, C., & Alter, M. (2012) · Kidney & Blood Pressure Research · doi:10.1159/000339028 · Cited by 145
Glucagon-like Peptide–1 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents
Gallwitz, B. (2011) · Drugs · doi:10.2165/11592810-000000000-00000 · Cited by 142
Glucagon‐like peptide‐1‐based therapies and cardiovascular disease: looking beyond glycaemic control
Anagnostis, P. G., Athyros, V. G., Adamidou, F., Panagiotou, A., Kita, M. D., Karagiannis, A. I., & Mikhailidis, D. P. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01345.x · Cited by 143
Elective peri‐operative management of adults taking glucagon‐like peptide‐1 receptor agonists, glucose‐dependent insulinotropic peptide agonists and sodium‐glucose cotransporter‐2 inhibitors: a multidisciplinary consensus statement: A consensus statement from the Association of Anaesthetists, Association of British Clinical Diabetologists, British Obesity and Metabolic Surgery Society, Centre for Perioperative Care, Joint British Diabetes Societies for Inpatient Care, Royal College of Anaesthetists, Society for Obesity and Bariatric Anaesthesia and UK Clinical Pharmacy Association
El‐Boghdadly, K., Dhesi, J., Fabb, P., Levy, N., Lobo, D. N., McKechnie, A., Mustafa, O., Newland‐Jones, P., Patel, A., Pournaras, D. J., et al. (2025) · Anaesthesia · doi:10.1111/anae.16541 · Cited by 147
Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus
Koliaki, C., & Doupis, J. (2011) · Diabetes Therapy · doi:10.1007/s13300-011-0002-3 · Cited by 140
Inactivation of the cardiomyocyte glucagon-like peptide-1 receptor (GLP-1R) unmasks cardiomyocyte-independent GLP-1R-mediated cardioprotection
Ussher, J. R., Baggio, L. L., Campbell, J. E., Mulvihill, E. E., Kim, M., Kabir, M. G., Cao, X., Baranek, B. M., Stoffers, D. A., Seeley, R. J., et al. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.04.009 · Cited by 144
Glucagon-Like Peptide-1 Limits Myocardial Stunning following Brief Coronary Occlusion and Reperfusion in Conscious Canines
Nikolaidis, L. A., Doverspike, A., Hentosz, T., Zourelias, L., Shen, Y.-T., Elahi, D., & Shannon, R. P. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.073890 · Cited by 137
Self-citation
The Cardiovascular Effects of GLP‐1 Receptor Agonists
Okerson, T., & CHILTON, R. J. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00256.x · Cited by 138
The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments
García‐Ropero, Á., Badimón, J. J., & Santos‐Gallego, C. G. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1551877 · Cited by 150
Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: Role of peripherally secreted and centrally produced peptides
Vrang, N., & Larsen, P. J. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.07.003 · Cited by 139
Perioperative management of long-acting glucagon-like peptide-1 (GLP-1) receptor agonists: concerns for delayed gastric emptying and pulmonary aspiration
van Zuylen, M. L., Siegelaar, S. E., Plummer, M. P., Deane, A. M., Hermanides, J., & Hulst, A. H. (2024) · British Journal of Anaesthesia · doi:10.1016/j.bja.2024.01.001 · Cited by 132
Glucagon Like Peptide-1 is Protective Against Myocardial Ischemia/Reperfusion Injury when Given Either as a Preconditioning Mimetic or at Reperfusion in an Isolated Rat Heart Model
Bose, A., Mocanu, M. M., Carr, R. D., & Yellon, D. M. (2005) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-005-6892-4 · Cited by 127
GLP-1 and cardioprotection: from bench to bedside
Ravassa, S., Zudaire, A., & Díez, J. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs123 · Cited by 126
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125
Targeting cell death in the reperfused heart: Pharmacological approaches for cardioprotection
Oerlemans, M. I. F. J., Koudstaal, S., Chamuleau, S. A. J., de Kleijn, D. P. V., Doevendans, P. A., & Sluijter, J. P. G. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.03.055 · Cited by 125
Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure
Liu, Q., Anderson, C. M., Broyde, A., Polizzi, C. J., Fernandez, R., Baron, A., & Parkes, D. G. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-76 · Cited by 125
Diabetic Cardiomyopathy
Murarka, S., & Movahed, M. R. (2010) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2010.07.249 · Cited by 125
Myocardial Ischaemia-reperfusion Injury is Attenuated by Intact Glucagon Like Peptide-1 (GLP-1) in the In Vitro Rat Heart and may Involve the p70s6K Pathway
Bose, A., Mocanu, M. M., Carr, R. D., & Yellon, D. M. (2007) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-007-6030-6 · Cited by 123
New Drugs for Type 2 Diabetes Mellitus
Krentz, A. J., Patel, M., & Bailey, C. J. (2008) · Drugs · doi:10.2165/00003495-200868150-00005 · Cited by 122
Incretins: their physiology and application in the treatment of diabetes mellitus
Tasyurek, H. M., Altunbas, H. A., Balci, M. K., & Sanlioglu, S. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2501 · Cited by 121
Emerging cardiovascular actions of the incretin hormone glucagon‐like peptide‐1: potential therapeutic benefits beyond glycaemic control?
Grieve, D., Cassidy, R. S., & Green, B. D. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00376.x · Cited by 122
Effects of liraglutide on left ventricular function in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention
Chen, W. R., Hu, S. Y., Chen, Y. D., Zhang, Y., Qian, G., Wang, J., Yang, J. J., Wang, Z. F., Tian, F., & Ning, Q. X. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.07.014 · Cited by 121
Incretin effect: GLP-1, GIP, DPP4
Kazakos, K. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(11)70011-0 · Cited by 129
Update on incretin hormones
Phillips, L. K., & Prins, J. B. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06491.x · Cited by 122
Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus
Holst, J. J., & Deacon, C. F. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.08.005 · Cited by 120
Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure
Yin, M., Silljé, H. H. W., Meissner, M., van Gilst, W. H., & de Boer, R. A. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-85 · Cited by 118
A Pilot Study to Assess Whether Glucagon-Like Peptide-1 Protects the Heart From Ischemic Dysfunction and Attenuates Stunning After Coronary Balloon Occlusion in Humans
Read, P. A., Hoole, S. P., White, P. A., Khan, F. Z., O'Sullivan, M., West, N. E. J., & Dutka, D. P. (2011) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.110.960476 · Cited by 119
Diabetic Cardiomyopathy
Schilling, J. D., & Mann, D. L. (2012) · Heart Failure Clinics · doi:10.1016/j.hfc.2012.06.007 · Cited by 120
Dipeptidyl peptidase IV inhibitors: A promising new therapeutic approach for the management of type 2 diabetes
Deacon, C. F., & Holst, J. J. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.09.011 · Cited by 117
Combine and conquer: advantages and disadvantages of fixed‐dose combination therapy
Bell, D. S. H. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12015 · Cited by 119
Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease
Read, P. A., Khan, F. Z., & Dutka, D. P. (2011) · Heart · doi:10.1136/hrt.2010.219345 · Cited by 114
GLP-1 receptor agonists and cardiovascular outcome trials: An update
Andrikou, E., Tsioufis, C. P., Andrikou, I., Leontsinis, I., Tousoulis, D. M., & Παπάνας, Ν. (2018) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2018.11.008 · Cited by 114
GLP ‐1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond
Ryan, D., & Acosta, A. (2015) · Obesity · doi:10.1002/oby.21107 · Cited by 112
Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials
Giorgino, F., Leonardini, A., & Laviola, L. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12044 · Cited by 113
Vildagliptin Improves Endothelium-Dependent Vasodilatation in Type 2 Diabetes
van Poppel, P. C. M., Netea, M. G., Smits, P., & Tack, C. J. (2011) · Diabetes Care · doi:10.2337/dc10-2421 · Cited by 112
Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury
Goto, H., Nomiyama, T., Mita, T., Yasunari, E., Azuma, K., Komiya, K., Arakawa, M., Jin, W. L., Kanazawa, A., Kawamori, R., et al. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.12.131 · Cited by 111
Therapy in the Early Stage: Incretins
Cernea, S., & Raz, I. (2011) · Diabetes Care · doi:10.2337/dc11-s223 · Cited by 114
DPP-4 inhibitors in the treatment of type 2 diabetes
Duez, H., Cariou, B., & Staels, B. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.11.028 · Cited by 118
G protein-coupled receptors as targets for anti-diabetic therapeutics
Oh, D. Y., & Olefsky, J. M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.4 · Cited by 110
Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin – diabetes control and potential adverse events
Åhrén, B. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.003 · Cited by 108
Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1
Riddle, M. C., & Drucker, D. J. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1267 · Cited by 108
Targeting β-Cell Function Early in the Course of Therapy for Type 2 Diabetes Mellitus
Leahy, J. L., Hirsch, I. B., PETERSON, K. A., & Schneider, D. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0668 · Cited by 110
Rationale and design of the EXenatide Study of Cardiovascular Event Lowering (EXSCEL) trial
Holman, R. R., Bethel, M. A., George, J. T., Sourij, H., Doran, Z., Keenan, J. F., Khurmi, N. S., Mentz, R. J., Oulhaj, A., Buse, J. B., et al. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.12.009 · Cited by 105
Realizing the clinical potential of ischemic preconditioning and postconditioning
Yellon, D. M., & Hausenloy, D. J. (2005) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0346 · Cited by 105
Albiglutide, a Long Lasting Glucagon-Like Peptide-1 Analog, Protects the Rat Heart against Ischemia/Reperfusion Injury: Evidence for Improving Cardiac Metabolic Efficiency
Bao, W., Aravindhan, K., Alsaid, H., Chendrimada, T. P., Szapacs, M. E., Citerone, D. R., Harpel, M. R., Willette, R. N., Lepore, J. J., & Jucker, B. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023570 · Cited by 106
GLP-1 promotes angiogenesis in human endothelial cells in a dose-dependent manner, through the Akt, Src and PKC pathways
Aronis, K. N., Chamberland, J. P., & Mantzoros, C. S. (2013) · Metabolism · doi:10.1016/j.metabol.2013.04.010 · Cited by 104
Sitagliptin attenuates cardiomyopathy by modulating the JAK/STAT signaling pathway in experimental diabetic rats
Alrasheed, N., Alrasheed, N., Hasan, I. H., Al-Amin, M., Al-Ajmi, H., & Mahmoud, A. (2016) · Drug Design, Development and Therapy · doi:10.2147/dddt.s109287 · Cited by 101
Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia–reperfusion injury
Chinda, K., Palee, S., Surinkaew, S., Phimphilai, M., Chattipakorn, S. C., & Chattipakorn, N. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.01.011 · Cited by 103
Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes
Paneni, F., & Lüscher, T. F. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.008 · Cited by 108
Therapeutic Manipulation of Myocardial Metabolism
Honka, H., Solis‐Herrera, C., Triplitt, C. L., Norton, L., Butler, J., & DeFronzo, R. A. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.02.057 · Cited by 101
The metabolic vicious cycle in heart failure
Opie, L. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17412-6 · Cited by 103
The potential effects of anti-diabetic medications on myocardial ischemia–reperfusion injury
Ye, Y., Perez-Polo, J. R., Aguilar, D. A., & Birnbaum, Y. (2011) · Basic Research in Cardiology · doi:10.1007/s00395-011-0216-6 · Cited by 101
Sitagliptin Reduces Cardiac Apoptosis, Hypertrophy and Fibrosis Primarily by Insulin-Dependent Mechanisms in Experimental type-II Diabetes. Potential Roles of GLP-1 Isoforms
Picatoste, B., Ramírez, E., Caro‐Vadillo, A., Iborra, C., Egido, J., Tuñón, J., & Lorenzo, Ó. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078330 · Cited by 103
Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits—the role of the GLP-1 receptor
Helmstädter, J., Keppeler, K., Küster, L., Münzel, T., Daiber, A., & Steven, S. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15462 · Cited by 99
Links between Metabolic Syndrome and Hypertension: The Relationship with the Current Antidiabetic Drugs
Stanciu, S. M., Rusu, E., Miricescu, D., Radu, A. C., Axinia, B., Vrabie, A.-M., Ionescu, R. F., Jinga, M., & Sîrbu, C. A. (2023) · Metabolites · doi:10.3390/metabo13010087 · Cited by 123
Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans
Bharucha, A. E., Charkoudian, N., Andrews, C. N., Camilleri, M., Sletten, D., Zinsmeister, A. R., & Low, P. A. (2008) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00153.2008 · Cited by 98
Pre-treatment with a DPP-4 Inhibitor is Infarct Sparing in Hearts from Obese, Pre-diabetic Rats
Huisamen, B., Genis, A., Marais, E., & Lochner, A. (2010) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-010-6271-7 · Cited by 96
Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis
Engel, S. S., Golm, G. T., Shapiro, D., Davies, M. J., Kaufman, K. D., & Goldstein, B. J. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-3 · Cited by 98
Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety
Nathanson, D., Ullman, B., Löfström, U., HEDMAN, A. G., Frick, M., Sjöholm, Å., & Nyström, T. (2012) · Diabetologia · doi:10.1007/s00125-011-2440-x · Cited by 96
Antioxidative potential of antidiabetic agents: A possible protective mechanism against vascular complications in diabetic patients
Yaribeygi, H., Butler, A. E., Barreto, G. E., & Sahebkar, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27278 · Cited by 100
GLP‐1: physiological effects and potential therapeutic applications
Aaboe, K., Krarup, T., Madsbad, S., & Holst, J. J. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00853.x · Cited by 99
Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner
Hausenloy, D. J., Whittington, H. J., Wynne, A. M., Begum, S. S., Theodorou, L., Riksen, N. P., Mocanu, M. M., & Yellon, D. M. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-154 · Cited by 96
GLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans
Subaran, S. C., Sauder, M. A., Chai, W., Jahn, L. A., Fowler, D. E., Aylor, K. W., Basu, A., & Liu, Z. (2014) · Clinical Science · doi:10.1042/cs20130708 · Cited by 95
Liraglutide: a once-daily GLP-1 analogue for the treatment of Type 2 diabetes mellitus
Vilsbøll, T. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.2.231 · Cited by 95
Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes
Åhrén, B. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210802584126 · Cited by 95
Cardiovascular effects of the DPP-4 inhibitors
Jose, T., & Inzucchi, S. E. (2012) · Diabetes and Vascular Disease Research · doi:10.1177/1479164111436236 · Cited by 97
Myocardial postconditioning: reperfusion injury revisited
Tsang, A., Hausenloy, D. J., & Yellon, D. M. (2005) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00091.2005 · Cited by 92
Newer GLP-1 receptor agonists and obesity-diabetes
Brown, E. E., Cuthbertson, D. J., & Wilding, J. P. H. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.009 · Cited by 92
The effect of dietary nitrate supplementation on the oxygen cost of cycling, walking performance and resting blood pressure in individuals with chronic obstructive pulmonary disease: A double blind placebo controlled, randomised control trial
Shepherd, A. I., Wilkerson, D. P., Dobson, L., Kelly, J., Winyard, P. G., Jones, A. M., Benjamin, N., Shore, A. C., & Gilchrist, M. (2015) · Nitric Oxide · doi:10.1016/j.niox.2015.01.002 · Cited by 88
Glucagon and Glucagon-Like Peptide Receptors as Drug Targets
Estall, J. L., & Drucker, D. J. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206776873671 · Cited by 88
Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction
Chen, W.-R., Shen, X., Zhang, Y., Chen, Y., Hu, S.-Y., Qian, G., Wang, J., Yang, J., Wang, Z., & Tian, F. (2015) · Endocrine · doi:10.1007/s12020-015-0798-0 · Cited by 88
Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin—based therapies
Ban, K., Hui, S., Drucker, D. J., & Husain, M. (2009) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2009.04.001 · Cited by 85
Diabetic cardiomyopathy: from pathophysiology to treatment.
Trachanas, K., Sideris, S. K., Aggeli, C., Poulidakis, E., Gatzoulis, K. A., Tousoulis, D. M., & Kallikazaros, I. E. (2014) · PubMed · Cited by 86
Lixisenatide for type 2 diabetes mellitus
Christensen, M., Knop, F. K., Vilsbøll, T., & Holst, J. J. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.562191 · Cited by 83
Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease
Yamaoka‐Tojo, M., Tojo, T., Takahira, N., Matsunaga, A., Aoyama, N., Masuda, T., & Izumi, T. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-17 · Cited by 86
Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes
Paneni, F., & Lüscher, T. F. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.015 · Cited by 83
Cardiovascular Effects of Glucagonlike peptide–1 Agonists
Davidson, M. H. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.03.046 · Cited by 84
DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes
Carolyn, F. D. (2007) · Frontiers in bioscience · doi:10.2741/2799 · Cited by 83
Glucagon-like Peptide-1 receptor Tie2+ cells are essential for the cardioprotective actions of liraglutide in mice with experimental myocardial infarction
McLean, B. A., Wong, C. K., Kabir, M. G., & Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101641 · Cited by 82
“Remarkably, despite a large body of evidence from animal and human studies that GLP-1RA preserve ventricular function and reduce the extent of MI within the left ventricle [12,13,55,56], our bulk RNA-seq analyses detected very few differentially expressed mRNA transcripts in the infarcted region or non-infarcted zone…”
Background
Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes
Garg, V., Verma, S., & Connelly, K. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.07.005 · Cited by 82
Cardioprotective GLP-1 metabolite prevents ischemic cardiac injury by inhibiting mitochondrial trifunctional protein-α
Siraj, M. A., Mundil, D., Beca, S., Momen, A., Shikatani, E. A., Afroze, T., Sun, X., Liu, Y., Ghaffari, S., Lee, W. L., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci99934 · Cited by 79
Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies
Wohlfart, P., Linz, W., Hübschle, T., Linz, D., Huber, J., Hess, S., Crowther, D., Ulrich, W., & Ruetten, H. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-84 · Cited by 79
A review of practical issues on the use of glucagon-like peptide-1 receptor agonists for the management of type 2 diabetes
Romera, I., Cebrián-Cuenca, A., Álvarez-Guisasola, F., Gomez-Peralta, F., & Reviriego, J. (2019) · Diabetes Therapy · doi:10.1007/s13300-018-0535-9 · Cited by 77
Targeting reperfusion injury in acute myocardial infarction: a review of reperfusion injury pharmacotherapy
Sharma, V., Bell, R. M., & Yellon, D. M. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.685163 · Cited by 77
The Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Improves Vascular Endothelial Function in Type 2 Diabetes
Kubota, Y., Miyamoto, M., Takagi, G., Ikeda, T., Kirinoki‐Ichikawa, S., Tanaka, K., & Mizuno, K. (2012) · Journal of Korean Medical Science · doi:10.3346/jkms.2012.27.11.1364 · Cited by 76
Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure
Arturi, F., Succurro, E., Miceli, S., Cloro, C., Ruffo, M., Maio, R., Perticone, M., Sesti, G., & Perticone, F. (2016) · Endocrine · doi:10.1007/s12020-016-1166-4 · Cited by 75
GLP-1 receptor agonists’ impact on cardio-renal outcomes and mortality in T2D with acute kidney disease
Pan, H.-C., Chen, J.-Y., Chen, H.-Y., Yeh, F.-Y., Sun, C.-Y., Huang, T. T.-M., & Wu, V.-C. (2024) · Nature Communications · doi:10.1038/s41467-024-50199-y · Cited by 75
Exenatide improves diastolic function and attenuates arterial stiffness but does not alter exercise capacity in individuals with type 2 diabetes
Scalzo, R. L., Moreau, K. L., Ozemek, C., Herlache, L., McMillin, S. L., Gilligan, S., Huebschmann, A. G., Bauer, T. A., Dorosz, J. L., Reusch, J. E. B., et al. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.10.003 · Cited by 75
Glucagon-like peptide-1 and glucagon-like peptide-2
Baggio, L. L., & Drucker, D. J. (2004) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2004.08.001 · Cited by 76
Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials
Zhong, J., Gong, Q., Goud, A., Srinivasamaharaj, S., & Rajagopalan, S. (2015) · Journal of Diabetes Research · doi:10.1155/2015/606031 · Cited by 74
Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: Results from an observational research
Irace, C., Luca, S. D., Shehaj, E., Carallo, C., Loprete, A., Scavelli, F. B., & Gnasso, A. (2012) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112449562 · Cited by 72
Lack of cardioprotection from subcutaneously and preischemic administered Liraglutide in a closed chest porcine ischemia reperfusion model
Kristensen, J., Mortensen, U. M., Schmidt, M., Nielsen, P. H., Nielsen, T. T., & Mæng, M. (2009) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-9-31 · Cited by 71
The PINK1/Parkin signaling pathway-mediated mitophagy: a forgotten protagonist in myocardial ischemia/reperfusion injury
Zhao, X., Wang, Z., Wang, L., Jiang, T., Dong, D., & Sun, M. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107466 · Cited by 76
Preconditioning and postconditioning: new strategies for cardioprotection
Hausenloy, D. J., & Yellon, D. M. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00762.x · Cited by 71
Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium
Wallner, M., Kolesnik, E., Ablasser, K., Khafaga, M., Wakula, P., Ljubojević-Holzer, S., Thon-Gutschi, E., Sourij, H., Kapl, M., Edmunds, N. J., et al. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.09.018 · Cited by 74
Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence
Natali, A., Nesti, L., Tricò, D., & Ferrannini, E. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01385-5 · Cited by 70
Semaglutide attenuates doxorubicin-induced cardiotoxicity by ameliorating BNIP3-Mediated mitochondrial dysfunction
Li, X., Luo, W., Tang, Y., Wu, J., Zhang, J., Chen, S., Lü, Z., Yu, T., Tang, Y., Wang, F., et al. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103129 · Cited by 74

Authors: Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P.
Affiliations: Allegheny General Hospital (US)
ORCID: Nikolaidis, Lazaros A.
Mankad, Sunil
Sokos, George G.
Venue: Circulation
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2004-03-02
Volume: 109
Issue: 8
Pages: 962-965
ISSN: 0009-7322 (ISSN-L)
1524-4539
DOI: 10.1161/01.cir.0000120505.91348.58
OpenAlex: W1968315455
Cited by: 901
References: 15
Citations by year: 2026: 9 · 2025: 16 · 2024: 25 · 2023: 18 · 2022: 17 · 2021: 25 · 2020: 27 · 2019: 38 · 2018: 37 · 2017: 46 · 2016: 48 · 2015: 63 · 2014: 71 · 2013: 80 · 2012: 92
FWCI: 16.30
Type: journal article
Language: en
Open access: closed
Locations: Circulation (publishedVersion)
PubMed (publishedVersion)
Funders: Pittsburgh Foundation
National Institutes of Health (5r01ag023125-05)
National Institute on Aging (1 R01 AG023125)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Ischemia and Reperfusion
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords: glucagon-like peptide-1, acute myocardial infarction, left ventricular dysfunction, primary percutaneous coronary intervention, reperfusion, left ventricular ejection fraction, regional wall motion, incretin-based therapy, glucose-insulin-potassium infusion, systolic dysfunction
MeSH terms: Adult, Aged, Aged, 80 and over, Blood Glucose, Combined Modality Therapy, Glucagon-Like Peptides, Female, Glucagon, Humans, Male, Middle Aged, Myocardial Infarction, Peptide Fragments, Pilot Projects, Safety, Stroke Volume, Angioplasty, Balloon, Coronary, Ventricular Function, Left, Treatment Outcome, Diabetes Complications, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks